ExodusPoint Capital Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.68M Sell
232,171
-24,672
-10% -$444K 0.02% 585
2026
Q2
$4.45M Buy
256,843
+95,143
+59% +$1.3M 0.03% 536
2026
Q1
$2.01M Sell
161,700
-664,299
-80% -$8.92M 0.02% 781
2025
Q4
$10.4M Buy
825,999
+83,186
+11% +$952K 0.08% 251
2025
Q3
$7.44M Buy
742,813
+211,032
+40% +$1.89M 0.08% 282
2025
Q2
$4.3M Buy
+531,781
New +$4.01M 0.04% 468
2025
Q1
– Sell
-108,267
Closed -$857K – 1429
2024
Q4
$857K Buy
+108,267
New +$908K 0.01% 993
2024
Q3
– Sell
-111,969
Closed -$711K – 1593
2024
Q2
$711K Buy
+111,969
New +$711K ﹤0.01% 1126
2023
Q4
– Sell
-47,484
Closed -$200K – 1430
2023
Q3
$200K Buy
+47,484
New +$177K ﹤0.01% 1525
2022
Q1
– Sell
-23,292
Closed -$112K – 2160
2021
Q4
$112K Buy
+23,292
New +$116K ﹤0.01% 1940
2021
Q3
– Sell
-42,032
Closed -$215K – 2069
2021
Q2
$215K Buy
+42,032
New +$239K ﹤0.01% 1942

Other funds holding AMRX

ExodusPoint Capital Management's AMRX Position: Q3 2026 in Review

ExodusPoint Capital Management reduced its Amneal Pharmaceuticals (AMRX) stake by 9.6% in Q3 2026, selling an estimated $444K and leaving 232,171 shares worth $4.68M. The position accounts for 0.02% of the portfolio, ranked #585.

ExodusPoint Capital Management first reported a position in AMRX in Q2 2021 and has held it in 11 quarters since. The position peaked at $10.4M in Q4 2025. 334 funds tracked by Wall St. Rank hold AMRX as of Q3 2026.

  • ExodusPoint Capital Management held 232,171 shares of Amneal Pharmaceuticals worth $4.68M as of Q3 2026.
  • ExodusPoint Capital Management sold 24,672 Amneal Pharmaceuticals shares in Q3 2026, an estimated $444K.
  • Amneal Pharmaceuticals made up 0.02% of ExodusPoint Capital Management's portfolio in Q3 2026, its #585 holding.
  • ExodusPoint Capital Management first reported a position in Amneal Pharmaceuticals in Q2 2021 and has held it in 11 quarters since.
  • ExodusPoint Capital Management's Amneal Pharmaceuticals position peaked at $10.4M in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q3 2026.

Based on ExodusPoint Capital Management's 13F filing for Q3 2026, filed 16 Nov 2026.